Anzeige
Mehr »
Login
Freitag, 23.02.2024 Börsentäglich über 12.000 News von 683 internationalen Medien
Ist das das Einstiegssignal vor der erneuten Rallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DW1Z | ISIN: US80880W1062 | Ticker-Symbol:
NASDAQ
22.02.24
21:59 Uhr
1,740 US-Dollar
-0,030
-1,69 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCILEX HOLDING COMPANY Chart 1 Jahr
5-Tage-Chart
SCILEX HOLDING COMPANY 5-Tage-Chart

Aktuelle News zur SCILEX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiScilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain3
16.02.Scilex Holding Co - 8-K, Current Report3
08.01.Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024243PALO ALTO, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
02.01.Scilex Holding Company estimates total product gross sales for fiscal year ended Dec 31 were between $150M and $155M3
02.01.Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information291PALO ALTO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
02.01.Scilex Holding Co - 8-K, Current Report2
26.12.23Scilex seeks Health Canada approval for migraine therapy4
26.12.23Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB for Acute Treatment of Migraine With or Without 260ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size...
► Artikel lesen
26.12.23Scilex files for $500M mixed securities shelf offering7
22.12.23Scilex Holding Co - 8-K, Current Report4
19.12.23Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba as a Liquid Colchicine Formulation Designed for Precision Dosing196Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Gout is a painful arthritic disorder affecting...
► Artikel lesen
15.12.23Scilex Announces Partner to Stock its Products3
15.12.23Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.1
06.12.23Scilex Holding Company announces that ZTlido (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State229PALO ALTO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
04.12.23Scilex Holding Company announces the addition of ZTlido (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee182PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
01.12.23Scilex Holding Company says total product gross sales for November $14M to $16M3
01.12.23Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Av285PALO ALTO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
01.12.23Scilex Holding Co - 8-K, Current Report1
30.11.23Scilex Holding Company announces successful FDA audit of enhanced ZTlido® manufacturing facility in Japan2
28.11.23Scilex Holding Company announces pharmacy initiative to stock ELYXYB in over 500 stores for a leading pharmacy chain in the U.S.221PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
Seite:  Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1